Association Between Malignancy and Topical Use of Pimecrolimus.
about
Current Management of Pediatric Vitiligo.Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.Acute Pustular Dermatosis, Following Topical Treatment With Pimecrolimus, in a Child Affected With Atopic and Contact Hand DermatitisHand dermatitis: a review of clinical features, prevention and treatment.Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: A cohort study.Advances in therapeutic strategies for the treatment of pruritus.Treatment of allergic children - Where is the progress (for the practicing allergist)?Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.Topical calcineurin inhibitors in eczema and cancer association: A cohort study.Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.Atopic Dermatitis Disease Complications.Atopic Dermatitis: Disease Background and Risk Factors.The safety of treatments used in pyoderma gangrenosum.Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation.A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study).
P2860
Q34478386-5D3701A9-2ACB-4071-82FF-5743AB11E8BBQ36042131-85C68583-FE15-4FAF-B65F-CF3182507C6BQ36652818-249B933A-29D4-4433-B358-B458E1E7CB08Q38446594-94E3DAFD-EBEE-442F-AF0C-64AA9A9C3ED6Q38619479-528359BD-1354-459D-A26E-F77DF71F179FQ38656850-8DCE817D-8768-45D3-B1A9-28CDAD5596CDQ38809512-8DFF65F6-E875-4D34-8498-02AA69E00619Q38860798-8E672518-B060-4978-90E0-B1CE0ED96F79Q39859545-126D94D9-81F7-4EF0-BD3D-B256812E3E8CQ46098786-67D72353-9BD5-4895-A3A8-52C8CA1968AAQ47602719-52373E14-CF6B-44AF-ADA4-59DBF903869DQ47602738-0B67799C-4F74-44C2-8972-E24C1140A40AQ47641664-09383A69-F808-4340-93E6-44B10CBFAB21Q50756733-66A54052-ECB8-4785-9159-72AAF5AEE778Q52646026-6D8F7CA5-24BD-443D-8D78-F6A67E034D75
P2860
Association Between Malignancy and Topical Use of Pimecrolimus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Association Between Malignancy and Topical Use of Pimecrolimus.
@ast
Association Between Malignancy and Topical Use of Pimecrolimus.
@en
type
label
Association Between Malignancy and Topical Use of Pimecrolimus.
@ast
Association Between Malignancy and Topical Use of Pimecrolimus.
@en
prefLabel
Association Between Malignancy and Topical Use of Pimecrolimus.
@ast
Association Between Malignancy and Topical Use of Pimecrolimus.
@en
P2093
P2860
P1433
P1476
Association Between Malignancy and Topical Use of Pimecrolimus.
@en
P2093
David J Margolis
Denise Raimondo
Ole J Hoffstad
Warren B Bilker
P2860
P304
P356
10.1001/JAMADERMATOL.2014.4305
P407
P577
2015-06-01T00:00:00Z